NCT05500612Recruiting
MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy
Magnetic Resonance Imaging of Hypoxia for Radiation Treatment Guidance in Glioblastoma Multiforme (MANGO)
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
This study is designed to evaluate the role of Oxygen Enhanced (OE) Magnetic resonance imaging (MRI) and Blood Oxygenation Level Dependent (BOLD) MRI in detecting regions of hypoxic tumour and to evaluate their use as imaging methods to selectively deliver targeted radiotherapy to regions of aggressive disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 9 Aug 2022
- Start date
- Aug 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- University of Sydney
- Diseases
- Glioblastoma
- NCT number
- NCT05500612
What you commit to
- Study type: Observational
- Planned participants: 20
- From Aug 2024 to the primary completion date, Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received anti - vascular endothelial growth factor (anti-VEGF) monoclonal antibody therapy the 3 months prior to recruitment
- Patients taking carbonic anhydrase inhibitors (Acetazolamide)
- Any implant, foreign body, 3 Tesla (3T) MRI incompatible device, or other contraindication to MRI imaging.
Other illness
- Patients with a history of psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.
- Patients with significant cardiac or pulmonary disease including cardiac arrythmias or Chronic Obstructive Pulmonary Disease (COPD) that are unable to tolerate high flow O2 for oxygen contrast.
- History of glaucoma
Lab values
- Patients with a history of severe renal disease(s) (eGFR \<20) that cannot tolerate gadolinium chelate contrast agents.
Other
- Women lactating, pregnant or of childbearing potential who are not willing to avoid pregnancy during the study
- Geographically remote patients unable to agree to imaging schedule
Who the study is looking for
- Suspected high-grade glioma (HGG) / glioblastoma multiforme (WHO grade IV) at initial radiological examination
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
- Available for scanning on two separate days
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| North Shore Private Hospital Coordinator of this site? Confirm its status | St Leonards | Australia | Not yet recruiting |
| Royal North Shore Hospital Coordinator of this site? Confirm its status | St Leonards | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.